Successful treatment of systemic mastocytosis with high-dose interferon-alfa

Long-term follow-up of a case

Joseph H. Butterfield, Ayalew Tefferi, Gerald F. Kozuh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalLeukemia Research
Volume29
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Systemic Mastocytosis
Interferon-alpha
interferon alfa-2b
Mast Cells
Tryptases
Calcitonin
Prostaglandins F
Hypothyroidism
Serum
Thyroxine
Therapeutics
Bone Marrow
Mutation

Keywords

  • c-kit mutation
  • Interferon-alfa
  • Prostaglandin F
  • Systemic mastocytosis therapy
  • Tryptase

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Successful treatment of systemic mastocytosis with high-dose interferon-alfa : Long-term follow-up of a case. / Butterfield, Joseph H.; Tefferi, Ayalew; Kozuh, Gerald F.

In: Leukemia Research, Vol. 29, No. 2, 02.2005, p. 131-134.

Research output: Contribution to journalArticle

@article{7e7d1f5c922247b09e34b95490202d27,
title = "Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case",
abstract = "Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5{\%}, and there was a decrease (urinary N-methylhistamine excretion, 75{\%}; serum tryptase concentration, 98{\%}) or normalization (serum calcitonin value, urinary prostaglandin F 2α excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.",
keywords = "c-kit mutation, Interferon-alfa, Prostaglandin F, Systemic mastocytosis therapy, Tryptase",
author = "Butterfield, {Joseph H.} and Ayalew Tefferi and Kozuh, {Gerald F.}",
year = "2005",
month = "2",
doi = "10.1016/j.leukres.2004.05.003",
language = "English (US)",
volume = "29",
pages = "131--134",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Successful treatment of systemic mastocytosis with high-dose interferon-alfa

T2 - Long-term follow-up of a case

AU - Butterfield, Joseph H.

AU - Tefferi, Ayalew

AU - Kozuh, Gerald F.

PY - 2005/2

Y1 - 2005/2

N2 - Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F 2α excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

AB - Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F 2α excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

KW - c-kit mutation

KW - Interferon-alfa

KW - Prostaglandin F

KW - Systemic mastocytosis therapy

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=10644277956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644277956&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.05.003

DO - 10.1016/j.leukres.2004.05.003

M3 - Article

VL - 29

SP - 131

EP - 134

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -